<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:st1="urn:schemas-microsoft-com:office:smarttags" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<META HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 11 (filtered medium)">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><o:SmartTagType
namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="Street"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="address"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="country-region"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="City"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="place"/>
<!--[if !mso]>
<style>
st1\:*{behavior:url(#default#ieooui) }
</style>
<![endif]-->
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman";}
a:link, span.MsoHyperlink
{color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{color:blue;
text-decoration:underline;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:Arial;
color:navy;}
@page Section1
{size:8.5in 11.0in;
margin:.5in .5in .5in .5in;}
div.Section1
{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body bgcolor=white lang=EN-US link=blue vlink=blue>
<div class=Section1>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'>Great if Dr. Sharma would be able to send
serum samples to you for evaluating your species-specific exo-antigens.<o:p></o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'><o:p> </o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'>KP<o:p></o:p></span></font></p>
<p class=MsoNormal><font size=2 color=navy face=Arial><span style='font-size:
10.0pt;font-family:Arial;color:navy'><o:p> </o:p></span></font></p>
<div>
<div class=MsoNormal align=center style='text-align:center'><font size=3
face="Times New Roman"><span style='font-size:12.0pt'>
<hr size=2 width="100%" align=center tabindex=-1>
</span></font></div>
<p class=MsoNormal><b><font size=2 face=Tahoma><span style='font-size:10.0pt;
font-family:Tahoma;font-weight:bold'>From:</span></font></b><font size=2
face=Tahoma><span style='font-size:10.0pt;font-family:Tahoma'> Raj
[mailto:raj@cellabs.com.au] <br>
<b><span style='font-weight:bold'>Sent:</span></b> Tuesday, May 31, 2011 9:18
PM<br>
<b><span style='font-weight:bold'>To:</span></b> Hanafi, Hanafi CTR EG NAMRU3 ;
Chang, Kwang-Poo; nandlals@hotmail.com; leish-l@lineu.icb.usp.br<br>
<b><span style='font-weight:bold'>Subject:</span></b> cutaneous form of leish
in Indian region</span></font><o:p></o:p></p>
</div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
<div>
<div>
<p class=MsoNormal><st1:Street w:st="on"><st1:address w:st="on"><font size=2
face=Arial><span style='font-size:10.0pt;font-family:Arial'>G'Day Dr</span></font></st1:address></st1:Street><font
size=2 face=Arial><span style='font-size:10.0pt;font-family:Arial'> Hanafi,<o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>My enquiry was to know whether <em><i><font face=Arial><span
style='font-family:Arial'>L. donovani</span></font></i></em> in <st1:country-region
w:st="on"><st1:place w:st="on">India</st1:place></st1:country-region>
produces a cutaneous form of lesion or not (I am not referring
to PKDL form). There are many reports from SriLanka about the cutaneous
manifestations by <em><i><font face=Arial><span style='font-family:Arial'>L.
donovani</span></font></i></em>. The PKDL although is a
cutaneous response appears very late in the infection process
and this is ascribed to be a protective response against the
parasite. <o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'> <o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Prof Chang mentioned <o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>"Analyses of several batches of basically clinical CL
samples from Dr. Sharma showed evidence of L infantum, but also L tropica as
well as a mixture of the two in one sample. This is the same picture we have
noted for samples from <st1:place w:st="on"><st1:City w:st="on">Hatay</st1:City>,
<st1:country-region w:st="on">Turkey</st1:country-region></st1:place>."
This is from <st1:place w:st="on">Sutlej</st1:place> region." It means
this cutaneous complex requires some investigation. <o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'> <o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>I raise species-specific exo-antigens from <em><i><font
face=Arial><span style='font-family:Arial'>L. tropica</span></font></i></em>
and <em><i><font face=Arial><span style='font-family:Arial'>L infantum</span></font></i></em>
and I am prepared to test the serum /plasma samples for presence of
antibodies. If Dr NL Sharma is prepared to send me specimens as well as
clinical plasma or serum samples I would be interested to investigate the
antibody response in these situations. <o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'> <o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Dr Raj<o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Cellabs<o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>----- Original Message ----- <o:p></o:p></span></font></p>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>From: "Hanafi, Hanafi CTR EG NAMRU3 " <<a
href="mailto:hanafi.hanafi.ctr.eg@med.navy.mil">hanafi.hanafi.ctr.eg@med.navy.mil</a>><o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>To: "Raj" <<a href="mailto:raj@cellabs.com.au">raj@cellabs.com.au</a>>;
<<a href="mailto:leish-l@lineu.icb.usp.br">leish-l@lineu.icb.usp.br</a>><o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Sent: Tuesday, May 31, 2011 6:19 PM<o:p></o:p></span></font></p>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Subject: RE: [Leish-l] Leish-l Digest, Vol 41, Issue 9<o:p></o:p></span></font></p>
</div>
</div>
<div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'><o:p> </o:p></span></font></p>
</div>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>> Dear Dr Raj:<br>
> <br>
> I think you mean PKDL (post kala azar dermal leishmanisis) caused by L.<br>
> donovani and it usually seen as a late complication of the disease. PKDL
has<br>
> been reported in <st1:country-region w:st="on">India</st1:country-region>,
<st1:country-region w:st="on">Kenya</st1:country-region> and <st1:country-region
w:st="on"><st1:place w:st="on">Sudan</st1:place></st1:country-region>.<br>
> <br>
> Thank you <br>
> R/<br>
> Hanafi<br>
> <br>
> Hanafi A. Hanafi, Ph. D.<br>
> Medical Research Scientist<br>
> Vector Biology Research Program<br>
> <st1:country-region w:st="on"><st1:place w:st="on">U.S.</st1:place></st1:country-region>
Naval Medical Research Unit No.3<br>
> <st1:place w:st="on"><st1:City w:st="on">Cairo</st1:City>, <st1:country-region
w:st="on">Egypt</st1:country-region></st1:place><br>
> Tel & Fax: ++2-02-2342-3090<br>
> E-mail: <a href="mailto:hanafi.hanafi.ctr.eg@med.navy.mil">hanafi.hanafi.ctr.eg@med.navy.mil</a><br>
> <a
href="mailto:yahanafi@yahoo.com">yahanafi@yahoo.com</a><br>
> </span></font><o:p></o:p></p>
</div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><br>
<br>
<br>
<br>
</span></font><font size=2 face=Tahoma><span style='font-size:10.0pt;
font-family:Tahoma'><br>
=======<br>
Email scanned by PC Tools - No viruses or spyware found.<br>
(Email Guard: 7.0.0.21, Virus/Spyware Database: 6.17630)<br>
<a href="http://www.pctools.com/?cclick=EmailFooterClean_51">http://www.pctools.com</a><br>
=======</span></font> <o:p></o:p></p>
</div>
</body>
</html>